Why the study?
Familial HCM gene mutation carriers without overt LVH can harbor subclinical cardiovascular changes, but conventional echocardiographic ejection fraction remains normal.
Are Velocity Vector Imaging (VVI) and NT-proBNP more sensitive than conventional echocardiography ejection fraction to evaluate heart function in familial HCM gene mutation carriers without overt left ventricular hypertrophy?
Are Velocity Vector Imaging (VVI) and NT-proBNP more sensitive than conventional echocardiography ejection fraction to evaluate heart function in familial HCM gene mutation carriers without overt left ventricular hypertrophy?
The study aims to determine if VVI and NT-proBNP can detect subclinical heart function changes in preclinical HCM better than conventional ejection fraction.
May support VVI and NT-proBNP for subclinical HCM detection; leaves open superiority to ejection fraction pending prospective validation.
Background and aim: Familial HCM gene mutation carriers without overt left ventricular hypertrophy (gene positive/phenotype negative G+/P-) can harbor subclinical changes in cardiovascular structure and function that precede the development of Hypertrophic Cardiomyopathy (HCM). Conventional echocardiography parameter ejection fraction is normal in HCM patients. We sought to investigate whether Velocity Vector Imaging (VVI) and NT-proBNP are more sensitive to evaluate heart function.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: